The Egyptian Drug Authority (EDA), under the leadership of Dr. Ali El Ghamrawy, held a virtual strategic meeting with Swissmedic, the Swiss Agency for Therapeutic Products, 19th September 2026. Led by Ms. Vincenza Trivigno, Chief Executive Officer of Swissmedic, the discussions centered on deepening the pharmaceutical regulatory partnership and advancing collaborative efforts in critical areas affecting Egypt’s drug approval and manufacturing frameworks.
Focus Areas of the Pharmaceutical Regulatory Partnership
The pharmaceutical regulatory partnership agenda encompassed several key priorities designed to elevate Egypt’s regulatory infrastructure. Primary discussion points included strengthening Good Manufacturing Practices (GMP) standards, accessing specialized technical expertise, and implementing comprehensive capacity building programs. Both organizations emphasized the importance of aligning Egypt’s regulatory approaches with the latest international pharmaceutical regulatory standards and best practices established globally.
Strategic Commitment to Regulatory Excellence
Dr. Ali El Ghamrawy commended the existing depth of cooperation between the EDA and Swissmedic, recognizing Switzerland’s advanced regulatory expertise as instrumental for enhancing Egypt’s institutional capabilities.
Ms. Vincenza Trivigno, representing Swissmedic, reciprocated the commitment by acknowledging the value of the pharmaceutical regulatory partnership and expressing confidence in further developing areas of mutual cooperation. She highlighted how the exchange of regulatory best practices supports the development of technical and institutional capacities.
Implementation of Practical Training and Knowledge Exchange
Both organizations discussed concrete mechanisms for executing practical training programs and facilitating technical knowledge exchange initiatives. These collaborative efforts aim to strengthen regulatory practices throughout Egypt’s pharmaceutical sector while ensuring continued alignment with internationally recognized pharmaceutical regulatory standards. The training frameworks will specifically address Good Manufacturing Practices (GMP) compliance and other essential areas in pharmaceutical regulation.
The pharmaceutical regulatory partnership represents a significant step in the EDA’s broader strategy to engage with leading international regulatory authorities. This engagement supports the Egyptian Drug Authority’s vision of maintaining institutional excellence and ensuring that Egypt’s pharmaceutical manufacturing sector operates under the most rigorous standards. Such cooperation directly benefits public health outcomes by guaranteeing the quality, safety, and efficacy of pharmaceutical products and vaccines distributed within Egypt and across regional markets.
This pharmaceutical regulatory partnership underscores the Egyptian Drug Authority’s ongoing commitment to regulatory excellence, driven by active collaboration with global peers and strategic alliances that enhance institutional capacity.
